Pulse.

a daily field guide to health research that matters

◆ Console

‹ Tue · 27 Oct 2026
Standard addition

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Single-agent immunotherapy offers endometrial cancer patients longer survival than chemotherapy with milder side effects.

A need exists for first-line chemotherapy-free options in advanced or recurrent endometrial cancer. First-line pembrolizumab showed a statistically significant and clinically meaningful improvement in progression-free survival, with lower frequency of overall and grade 3 or above treatment-related adverse events.

What the study was

Study design
Randomized controlled trial
Sample size
150
Category
Other
Maturity
Potentially Practice-Changing
Journal
Lancet

Why it surfaced

Randomized controlled trial; human evidence; PubMed abstract reviewed; conservative rubric score 9/10.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.